InsiderClue
← All stocks

Travere Therapeutics, Inc.

TVTX Net selling
CIK 0001438533 #1223 in the set updated 17 Sep 2026
Bought (120 mo)
$89.25K
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$64.26M
$14.01M on a plan · $34.80M straight out of an exercise
Sold at will
$15.45M
267 of 395 sales
Net
−$64.17M
−$15.36M against sales at will

By person

21 insiders · 397 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Dube Eric M
CHIEF EXECUTIVE OFFICER
—
$21.24M (45) scheduled
−$21.24M
432,886
0.4592%
$29.47M
—
ASELAGE STEVE
Director
$89.25K (1)
$7.30M (40) scheduled
−$7.21M
166,419
0.1766%
$11.33M
−50.4%
REED ELIZABETH E
Chief Legal Officer and GC
—
$6.93M (66) scheduled
−$6.93M
105,211
0.1116%
$7.16M
+6,799%
Calvin Sandra
SVP, CHIEF ACCOUNTING OFFICER
—
$5.96M (27) scheduled
−$5.96M
42,353
0.0449%
$2.88M
+40.5%
ROTE WILLIAM E.
Chief Research Officer
—
$5.22M (53) scheduled
−$5.22M
115,474
0.1225%
$7.86M
+1,018%
Baynes Roy D.
Director
—
$3.09M (8) scheduled
−$3.09M
41,500
0.0440%
$2.83M
+937.5%
Inrig Jula
CHIEF MEDICAL OFFICER
—
$2.72M (24) scheduled
−$2.72M
112,770
0.1196%
$7.68M
—
Meckler Jeffrey A
Director
—
$2.27M (6) scheduled
−$2.27M
91,500
0.0971%
$6.23M
+69.4%
Heerma Peter
CHIEF COMMERCIAL OFFICER
—
$2.04M (28)
−$2.04M
140,684
0.1492%
$9.58M
+1,210%
Clague Laura
Chief Financial Officer
—
$1.93M (35)
−$1.93M
35,655
0.0378%
$2.43M
—
Cline Christopher R.
CHIEF FINANCIAL OFFICER
—
$1.82M (28) scheduled
−$1.82M
118,016
0.1252%
$8.04M
+310.9%
LYONS GARY A
Director
—
$1.55M (8) scheduled
−$1.55M
61,500
0.0652%
$4.19M
+156.3%
Coughlin Timothy
Director
—
$1.27M (3) scheduled
−$1.27M
56,250
0.0597%
$3.83M
+155.7%
McFarlane Neil F.
Chief Operating Officer
—
$552.56K (7)
−$552.56K
26,988
0.0286%
$1.84M
+56.1%
Rosenberg Noah L.
Chief Medical Officer
—
$366.78K (17)
−$366.78K
47,614
0.0505%
$3.24M
+2,185%
Squarer Ron
Director
—
—
—
39,375
0.0418%
$2.68M
—
Orwin John A
Director
—
—
—
39,375
0.0418%
$2.68M
—
Poole Sandra
Director
—
—
—
34,000
0.0361%
$2.31M
—
Bruhn Suzanne Louise
Director
—
—
—
32,750
0.0347%
$2.23M
—
Williams Brinkley Ruth
Director
—
—
—
29,750
0.0316%
$2.03M
—
KOZARICH JOHN W
Director
—
—
—
29,000
0.0308%
$1.97M
+31.8%

Individual transactions

59
Insider
Date
Role
Action
Shares
Price
Amount
Meckler Jeffrey A
10 Sep 2026
Director
Sold after exercise
3,100
$68.09
$211.07K
Meckler Jeffrey A
10 Sep 2026
Director
Sold after exercise
14,000
$67.46
$944.49K
Meckler Jeffrey A
10 Sep 2026
Director
Sold after exercise
1,200
$66.15
$79.38K
Meckler Jeffrey A
10 Sep 2026
Director
Sold after exercise
1,700
$65.39
$111.17K
LYONS GARY A
18 Aug 2026
Director
Sold after exercise
900
$63.86
$57.47K
LYONS GARY A
18 Aug 2026
Director
Sold after exercise
4,100
$63.27
$259.39K
LYONS GARY A
17 Aug 2026
Director
Sold after exercise
500
$64.16
$32.08K
LYONS GARY A
17 Aug 2026
Director
Sold after exercise
2,600
$63.50
$165.10K
LYONS GARY A
17 Aug 2026
Director
Sold after exercise
1,900
$62.53
$118.80K
Baynes Roy D.
12 Jun 2026
Director
Sold after exercise
4,500
$50.00
$225.00K
Coughlin Timothy
12 Jun 2026
Director
Sold after exercise
10,000
$50.07
$500.75K
Baynes Roy D.
5 May 2026
Director
Sold after exercise
4,500
$46.65
$209.93K
Inrig Jula
4 May 2026
CHIEF MEDICAL OFFICER
Sold after exercise
20,000
$45.00
$900.00K
REED ELIZABETH E
4 May 2026
Chief Legal Officer and GC
Sold after exercise
20,000
$45.00
$900.00K
Meckler Jeffrey A
4 May 2026
Director
Sold after exercise
8,000
$45.00
$360.00K
Baynes Roy D.
1 May 2026
Director
Sold after exercise
9,750
$44.22
$431.15K
REED ELIZABETH E
14 Apr 2026
Chief Legal Officer and GC
Sold after exercise
7,215
$41.93
$302.52K
REED ELIZABETH E
14 Apr 2026
Chief Legal Officer and GC
Sold after exercise
37,500
$41.07
$1.54M
Calvin Sandra
14 Apr 2026
SVP, CHIEF ACCOUNTING OFFICER
Sold after exercise
21,977
$41.07
$902.60K
Baynes Roy D.
14 Apr 2026
Director
Sold after exercise
6,750
$42.12
$284.31K
Baynes Roy D.
14 Apr 2026
Director
Sold after exercise
26,000
$41.07
$1.07M
LYONS GARY A
14 Apr 2026
Director
Sold after exercise
8,000
$41.07
$328.56K
Baynes Roy D.
6 Apr 2026
Director
Sold after exercise
10,000
$33.00
$330.00K
REED ELIZABETH E
1 Apr 2026
Chief Legal Officer and GC
Sold after exercise
10,000
$30.00
$300.00K
Dube Eric M
1 Apr 2026
CHIEF EXECUTIVE OFFICER
Sold after exercise
25,098
$31.46
$789.58K
Dube Eric M
1 Apr 2026
CHIEF EXECUTIVE OFFICER
Sold after exercise
34,902
$30.55
$1.07M
REED ELIZABETH E
16 Mar 2026
Chief Legal Officer and GC
Sold after exercise
10,000
$28.09
$280.86K
Dube Eric M
20 Feb 2026
CHIEF EXECUTIVE OFFICER
Sold after exercise
60,000
$30.10
$1.81M
REED ELIZABETH E
17 Feb 2026
Chief Legal Officer and GC
Sold after exercise
4,321
$28.26
$122.12K
REED ELIZABETH E
17 Feb 2026
Chief Legal Officer and GC
Sold after exercise
5,679
$27.50
$156.20K
Dube Eric M
27 Jan 2026
CHIEF EXECUTIVE OFFICER
Sold after exercise
51,865
$30.10
$1.56M
Dube Eric M
23 Jan 2026
CHIEF EXECUTIVE OFFICER
Sold after exercise
8,135
$30.01
$244.15K
REED ELIZABETH E
20 Jan 2026
Chief Legal Officer and GC
Sold after exercise
10,000
$27.34
$273.42K
Inrig Jula
24 Dec 2025
CHIEF MEDICAL OFFICER
Sold after exercise
15,000
$42.00
$630.00K
ROTE WILLIAM E.
24 Dec 2025
Chief Research Officer
Sold after exercise
60,000
$40.10
$2.41M
Cline Christopher R.
1 Dec 2025
CHIEF FINANCIAL OFFICER
Sold after exercise
20,000
$35.01
$700.20K
Calvin Sandra
4 Nov 2025
SVP, CHIEF ACCOUNTING OFFICER
Sold after exercise
67,115
$36.00
$2.42M
Coughlin Timothy
31 Oct 2025
Director
Sold after exercise
18,000
$35.03
$630.60K
Dube Eric M
29 Oct 2025
CHIEF EXECUTIVE OFFICER
Sold after exercise
27,128
$30.12
$817.07K
Dube Eric M
28 Oct 2025
CHIEF EXECUTIVE OFFICER
Sold after exercise
92,872
$30.38
$2.82M
REED ELIZABETH E
22 Sep 2025
Chief Legal Officer and GC
Sold after exercise
10,000
$25.00
$250.00K
Calvin Sandra
11 Feb 2025
SVP, CHIEF ACCOUNTING OFFICER
Sold after exercise
9,244
$25.00
$231.10K
Calvin Sandra
11 Feb 2025
SVP, CHIEF ACCOUNTING OFFICER
Sold after exercise
15,000
$25.00
$375.00K
Calvin Sandra
11 Feb 2025
SVP, CHIEF ACCOUNTING OFFICER
Sold after exercise
10,000
$25.00
$250.00K
Calvin Sandra
11 Feb 2025
SVP, CHIEF ACCOUNTING OFFICER
Sold after exercise
10,000
$25.00
$250.00K
Calvin Sandra
11 Feb 2025
SVP, CHIEF ACCOUNTING OFFICER
Sold after exercise
10,000
$25.00
$250.00K
Baynes Roy D.
6 Feb 2025
Director
Sold after exercise
10,000
$22.00
$220.00K
Baynes Roy D.
23 Jan 2025
Director
Sold after exercise
16,000
$20.00
$320.00K
Calvin Sandra
26 Dec 2024
SVP, CHIEF ACCOUNTING OFFICER
Sold after exercise
15,000
$17.22
$258.28K
Calvin Sandra
25 Nov 2024
SVP, CHIEF ACCOUNTING OFFICER
Sold after exercise
12,090
$18.30
$221.26K
LYONS GARY A
4 Oct 2024
Director
Sold after exercise
18,821
$15.15
$285.23K
LYONS GARY A
4 Oct 2024
Director
Sold after exercise
21,179
$14.35
$303.87K
Meckler Jeffrey A
30 Sep 2024
Director
Sold after exercise
40,000
$14.06
$562.32K
ASELAGE STEVE
5 Nov 2021
Director
Sold after exercise
10,000
$26.23
$262.30K
ASELAGE STEVE
7 Oct 2021
Director
Sold after exercise
32,000
$26.26
$840.32K
ASELAGE STEVE
7 Oct 2021
Director
Sold after exercise
28,000
$26.23
$734.44K
ASELAGE STEVE
16 Apr 2021
Director
Sold after exercise
10,000
$26.23
$262.30K
ASELAGE STEVE
17 Mar 2021
Director
Sold after exercise
7,727
$27.56
$212.96K
ASELAGE STEVE
17 Mar 2021
Director
Sold after exercise
10,000
$27.35
$273.50K
Showing 250 of 397 transactions. The figures above use every one of them.

What was left out

Form 4 filings counted 416
Amendments (4/A) skipped 1
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 67
Sales straight out of an exercise 61
Sales at will 267
Transactions with no price 0
Shares from compensation/vesting 3,710,979
Sales filed before the plan box existed 219
History held since 2 Sep 2016